Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Kan Jang is a standardized herbal medicinal product composed of extracts from *Andrographis paniculata* (commonly known as "andrographis") and *Eleutherococcus senticosus* ("Siberian ginseng" or "eleuthero"), sometimes also including *Echinacea purpurea* and *Justicia adhatoda* depending on the formulation. It is primarily used for the relief of symptoms associated with viral respiratory tract infections such as the common cold, influenza, and mild COVID-19. The mechanism of action involves antiviral, immunomodulatory, and anti-inflammatory effects attributed mainly to diterpenoid lactones (andrographolides) from *Andrographis paniculata*. These compounds inhibit inflammatory mediators like NO production and COX-2 expression; they may also modulate immune responses via TLR4/NF-kappaB signaling pathway inhibition. Kan Jang has been shown in clinical studies to reduce symptom severity (sore throat, cough, runny nose), decrease disease progression rates in mild COVID-19 patients compared to placebo, shorten illness duration by about two days versus placebo for colds/flu-like illnesses[1][2][8]. It is registered as a traditional herbal medicine in several countries since 1997.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Kan Jang.